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Table
Clinical outcomes of 9/10 MMURD versus 10/10 MUD by HLA-speciﬁc allele.
Pooled RR (95% CI) Grade II-IV
Acute GVHD
Grade III-IV
Acute GVHD
Chronic
GVHD
Disease-Free
Survival
Overall
Survival
HLA-A 1.12 (0.75-1.66) 1.57 (1.29-1.90) 0.99 (0.68-1.45) 1.20 (1.00-1.45) 1.47 (1.31-1.65)
HLA-B 1.41 (0.63-3.12) 1.67 (1.37-2.03) 0.87 (0.56-1.36) 1.20 (1.04-1.38) 1.33 (1.18-1.51)
HLA-C 1.16 (1.04-1.28) 1.44 (1.25-1.65) 1.04 (0.94-1.16) 1.01 (0.73-1.38) 1.28 (1.13-1.46)
HLA-DRB1 1.60 (1.23-2.09) 1.39 (1.13-1.72) 1.11 (0.68-1.83) 1.16 (0.94-1.44) 1.36 (1.22-1.51)
HLA-DQB1 0.89 (0.37-2.14) insufﬁcient data insufﬁcient data 0.99 (0.71-1.37) 0.95 (0.69-1.31)
HLA-DPB1 2.68 (1.16-6.19) 1.20 (0.94-1.52) 1.06 (0.76-1.46) 0.85 (0.75-0.97) 0.98 (0.89-1.07)
Table
Patient characteristics.
Characteristic MRDnegn[60 MRDposn[20 p-value
Median age in years (range) 33 (1.3-64) 33(10-65) 0.90
Gender, n (%)
Female 28(47) 10 (50) 0.95
Male 32(53) 10 (50)
Race, n (%)
Caucasian 19(42) 26 (58) 0.14
Other 26(58) 19(42)
CMV seropositive , n (%) 44 (73) 13(65) 0.63
Transplant type, n (%)
Flu-Cy-l320 CGV TBI 37(62) 13(65) 1.00
Treo-Flu-200 cGY TBI 23(38) 7(35)
GVHD prophylaxis, n(%)
CSA + MMF 60(100) 20 (100) l.00
CR status, n (%)
1 40(65) 10 (5O) 0.31
2 20(35) 10 (50)
Disease risk
Low/intermediate 33 (55) 7(35) 0.11
High/very high 27(45) 13(65)
Abbreviations: MRD ¼ minimal residual disease, Flu ¼ Fludarabine,
Cy¼Cyclophosphamide, TBI¼ Total body irradiation,GVHD¼ graft versushost
disease, CSA ¼ cyclosporine, MMF¼ mycophenolate mofetil, CR ¼ complete
remission. 1. Signiﬁcance of minimal residual disease before myeloablative
allogeneic hematopoietic cell Transplantation for AML in ﬁrst and second
complete remission. Walter RB et al. Blood 2013;122(10):1813-21.
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MMURD transplant.
Methods: A comprehensive search of Medline and
EMBASE was performed through April 2014. We included
published manuscripts that reported outcomes of adult
patients with hematologic malignancies who underwent
MUD (matched at HLA-A, B, C and DRB1 at a minimum) or
MMURD transplant (single antigen or allele mismatch only).
The pooled relative risks (RR) from hazard ratios and risk
ratios and 95% conﬁdence intervals (CI) were estimated using
a DerSimonian-Laird random-effects model. Heterogeneity
was tested using the I2 statistic and Cochran Q test, and
sources of heterogeneity were evaluated using univariate
meta-regression. Statistical analyses were performed using
Stata v13.1.
Results: Twenty-two studies were included, representing
38,877 transplants. Nine out of 10 MMURD transplant was
associated with a higher risk of overall mortality compared
with 10 out of 10 MUD transplant (n¼10; RR 1.32, 95% CI
1.17e1.49). No signiﬁcant sources of heterogeneity were
identiﬁed. MMURD transplant was associated with worse
disease-free survival compared with MUD transplant (n¼6;
RR 1.20, 95% CI, 1.08e1.33). The pooled effect estimates for
grade II-IV acute and chronic GVHD were 1.23 (n¼4; 95% CI
0.99e1.53) and 1.08 (n¼3; 95% CI 0.76e1.54) respectively.
Single antigen/allele mismatches at HLA-A, B, C or DRB1
were associated with a higher risk of grade III-IV acute GVHD
and overall mortality, but not chronic GVHD as compared
with MUD transplant (Table). Disease-free survival was only
worse for HLA-B mismatch.
Conclusion: MMURD transplant is associated with
signiﬁcantly higher risk of overall mortality and acute GVHD,
but not chronic GVHD compared with MUD transplant. This
risk is associated with HLA-A, -B, -C, and eDRB1, but not
-DQB1 and -DPB1 mismatches.
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Background: Pre-transplant minimal residual disease
(MRD) is associated with inferior outcomes in patients with
acute myeloid leukemia (AML) undergoing myeloablative
hematopoietic cell transplantation (HCT) from related
and unrelated donors1. However data on the impact of
pre-transplant MRD after cord blood transplantation (CBT)
are limited. Using prospectively collected data, we reviewed
80 consecutive patients with AML who received a
myeloablative CBT between 2006 and 2013.
Methods: The myeloablative preparative regimen consisted
of TBI (1320 cGy), Cytoxan and Fludarabine (FLU) (n¼50;62%) or Treosulfan (Treo), FLU and 200 cGY TBI (n¼30; 38%).
Graft-versus-host-disease prophylaxis consisted of cyclo-
sporine and mycophenolate mofetil. Ten-color multiparam-
eter ﬂow cytometry studies on bone marrow aspirates were
performed before HCT to determine the presence of MRD.
Any level of residual disease was considered MRD-positive
(MRDpos).
Results: Pre-transplant MRD was identiﬁed in 20 (25%)
patients. The majority of patients (n¼67; 84%) received a
double-CB graft; the rest received a single-CB graft.
Pre-transplant demographic and clinical characteristics were
similar between the 2 groups (Table). Disease free survival
(DFS) at 5 years was 69% (95% CI: 55-79) and 52% (95% CI:
29-72) for MRDneg and MRDpos patients, respectively
(p¼0.08) (Figure 1A). Figure 1B and 1C show DFS by MRD
for patients receiving different conditioning regimen. After
adjusting for age, disease risk (low/intermediate vs. high/
very high), and CR status (CR1 vs. CR2), the relative
hazard of overall mortality (OM) in the MRDpos group
compared to the MRDneg group was suggestively different
with a HR¼2.36 (95%CI: 1.02-5.43; p¼0.04). However, the
impact of MRD on OM was only signiﬁcant in patients
receiving a Treo based regimen [(HR¼9.5; 95% CI 1.84-49.5)
p¼0.007] while no difference were seen in patients
receiving high-dose TBI [(HR¼1.28; 95% CI 0.44-3.74)
p¼0.64]. Cumulative incidence of relapse was signiﬁcantly
higher in MRDpos patients, 31% (95%CI: 13-52) vs. 10% (95%
CI: 4-20) in MRDneg (p¼0.01) for the group as a whole. An
higher proportion of relapses were observed in MRDpos
Figure 1. A) Disease free survival by pretransplant MRD status. B) Disease free survival by pretransplant MRD status in patients receiving high-dose TBI (1320 CGy),
cyclophosphamide and ﬂudarabine. C) Disease free survival by pretransplant MRD status in patients receiving treosulfan, ﬂudarabine, and a single fraction of 200CGy
TBI.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S54eS78S68patients receiving Treo [34% vs. 8% (p¼0.03)] while no
differences were observed in patients receiving high-dose
TBI [29% vs. 12% (p¼0.10)]. Incidence of non-relapse
mortality was 15% (95% CI: 4-34) and 19% (95%CI: 10-31)
for MRDpos and MRDneg patients, respectively (p¼0.81).
Conclusion: Herein we demonstrate that the presence of
pre-transplant MRD after myeloablative CBT is associated
overall with adverse outcomes. However, the presence of
pre-transplant MRD impacted outcomes less if the patient
received a high-dose TBI-based preparative regimen. Our
study suggests furthering extending the use of CBT with
high-dose TBI in AML MRDpos patients.54
Mismatched Unrelated Donor Allo-SCT for AML after
Reduced Intensity or Ablative Conditioning RegimendA
Report from the Acute Leukemia Working Party of the
EBMT
Bipin N. Savani 1, Myriam Labopin 2,3,4,5,
Emmanuelle Polge 2,3,4,5, Nicolaus Kröger 6, Jurgen Finke 7,
Gerhard Ehninger 8, Dietger Niederwieser 9,
Slawomira Kyrcz-Krzemien 10, Rainer Schwerdtfeger 11,
Donald W. Bunjes 12, Bertrum Glass 13, Gerard Socié 14,
Per T. Ljungman 15, Mohamad Mohty 2,3,4,5, Arnon Nagler 2,16.
1 Vanderbilt University Medical Center, Nashville, TN; 2 EBMT
Paris study ofﬁce / CEREST-TC, Paris, France; 3 Department of
Haematology, Saint Antoine Hospital, Paris, France; 4 INSERM
UMR 938, Paris, France; 5 Université Pierre et Marie Curie,
Paris, France; 6 Dept of Stem Cell Transplantation, University
Medical Center Hamburg, Hamburg, Germany; 7 Department of
Medicine, Haematology & Oncology, Allogeneic Stem Cell
Transplantation Section, Freiburg University Medical Center,
Freiburg, Germany; 8 Universitaetsklinikum Dresden, Dresden,
Germany; 9 University of Leipzig, Leipzig, Germany; 10 Silesian
Medical Academy, Katowice, Poland; 11 Department of BMT,
DKD - Wiesbaden, Wiesbaden, Germany; 12 Department of
Internal Medicine III, University of Ulm, Ulm, Germany;
13 Asklepios Klinik St. Georg - Department of Haematology,Hamburg, Germany; 14Hematology/Transplantation, Hospital
Saint Louis, Paris, France; 15Hematology, Karolinska University
Hospital, Stockholm, Sweden; 16 The Chaim Sheba Medical
Center, Tel-Hashomer, Division of Hematology and Bone
Marrow Transplantation, Ramat-Gan, Israel
Background: RIC regimens are reported to be associated
with equivalent outcome compared to ablative regimens
(MAC) but it is unknown if there are any outcome differences
after mismatched (MM) unrelated donor (URD) allo-SCT. We
hypothesized that, the historically higher relapse rate after
RIC compared to MAC can be abrogated by potent GVL effect
using MM URD.
Methods: Patients (pts) who underwent MAC or RIC MM
URD transplant from 2000-12 were included in the study. All
had donors with available information on HLA MM at one or
two loci (9/10 or 8/10). Regimens were classiﬁed as MAC or
RIC based on EBMT criteria. The Kaplan-Meier estimator, the
cumulative incidence function and Cox proportional hazards
regression models were used where appropriate.
Results: 1041 pts receiving MAC compared with 883 RIC
after MM-URD allo-SCT. Among the MAC, 872 (83.8%) were
9/10 and 169 (16.2%) 8/10 matched and in RIC cohort 754
(85.4%) were 9/10 and 129 (14.6%) were 8/10 matched.
Median follow up for MAC and RIC group was 27 and 23
months respectively. MAC recipients were signiﬁcantly
younger (median age 43 vs 57 year), 70% pts were <50 year
age in MAC vs only 30% in RIC group (p¼0.0001).
Signiﬁcantly higher numbers of pts had sAML (13 vs 10%,
p¼0.04) and KPS<90% (30 vs 25%, p¼0.02) in the RIC group.
There were no signiﬁcant differences in distributions of
advanced disease and poor risk cytogenetic among regimens.
Commonly used MAC regimens were TBI based (n¼369),
BuCy (354) and FluBu (143); and in the RIC group regimens
were low dose TBI based (n¼275), BuFlu (312) and FluMel
(178). The MAC group had more frequently marrow as the
stem cell source (20 vs 9%; p<0.0001). Percentages of
engraftment and grade II-IV aGVHD were not different
between the groups. The incidence of cGVHD was higher
